ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last821 to 840 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention Arm vs Placebo Arm: Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)189 of 5,780

230 of 5,764

-0.7 points

-1.4 to -0.0

11,544NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: Incidence of Perinatal Mortality264 of 5,779

309 of 5,763

-0.8 points

-1.6 to -0.0

11,542NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: Maternal Outcome 2 - Incidence of Antepartum Hemorrhage26 of 5,761

25 of 5,746

0.0 points

-0.2 to 0.3

11,507NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Benazepril / Amlodipine vs Benazepril / HCTZ: serious adverse events1,844 of 5,740

2,026 of 5,757

-3.1 points

-4.8 to -1.3

11,497NCT00170950

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Moderate to Severe Influenza A and/or B Disease Due to Antigenically-matching Influenza Strains.20 of 5,707

88 of 5,697

-1.2 points

-1.6 to -0.8

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Moderate to Severe Influenza A and/or B Disease Due to Any Seasonal Influenza Strain.79 of 5,707

216 of 5,697

-2.4 points

-3.0 to -1.8

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of RT-PCR Confirmed Severe Influenza A and/or B Due to Any Seasonal Influenza Strain.2 of 5,707

3 of 5,697

-0.0 points

-0.1 to 0.1

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With RT-PCR Confirmed Influenza of Any Severity.344 of 5,707

662 of 5,697

-5.6 points

-6.6 to -4.6

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Influenza A and/or B Disease of Any Severity Due to Antigenically-matching Influenza Strains88 of 5,707

216 of 5,697

-2.2 points

-2.9 to -1.7

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of Acute Otitis Media (AOM) With RT-PCR Confirmed Influenza A and/or B Infection Due to Any Seasonal Influenza Strain.12 of 5,707

28 of 5,697

-0.3 points

-0.5 to -0.1

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Influenza A and/or B Disease of Any Severity Due to Any Seasonal Influenza Strain.303 of 5,707

602 of 5,697

-5.3 points

-6.3 to -4.3

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza.90 of 5,707

242 of 5,697

-2.7 points

-3.3 to -2.1

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

D-QIV vs Control: Number of Subjects With First Occurrence of Lower Respiratory Illness (LRI) With RT-PCR Confirmed Influenza.28 of 5,707

61 of 5,697

-0.6 points

-0.9 to -0.3

11,404NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Intervention Arm vs Placebo Arm: Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g78 of 5,628

101 of 5,624

-0.4 points

-0.9 to 0.1

11,252NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g1,078 of 5,628

1,153 of 5,624

-1.3 points

-2.8 to 0.1

11,252NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Cardiovascular Disorders Digital Intervention Arm (CVD-I) vs Cardiovascular Disorders Without Digital Intervention Arm: Number of Participants With Self-reported Influenza Vaccination Status as Vaccinated3,418 of 5,575

3,355 of 5,662

2.1 points

0.2 to 3.9

11,237NCT04584645

A Digital Flu Intervention for People With Cardiovascular Conditions

Receives OUD-CDS vs Does Not Receive the OUD-CDS: deaths from any cause270 of 5,688

268 of 5,509

-0.1 points

-0.9 to 0.7

11,197NCT04198428

Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)

Receives OUD-CDS vs Does Not Receive the OUD-CDS: serious adverse events3,740 of 5,688

3,752 of 5,509

-2.4 points

-4.1 to -0.6

11,197NCT04198428

Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)

Open Group vs Masked Group: Number of Infants With Apgar Score < = 3 at 5 Minutes (Primary Outcome Component)17 of 5,532

6 of 5,576

0.2 points

0.0 to 0.4

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Infants Experiencing Neonatal Encephalopathy (Primary Outcome Component)4 of 5,532

5 of 5,576

-0.0 points

-0.1 to 0.1

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=42

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02409680-a525f01e",
        "title": "Intervention Arm vs Placebo Arm: Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)",
        "summary": "189 of 5780 against 230 of 5764; risk difference -0.7 points, 95% interval -1.4 to -0.0; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
        "record": "/library/comparisons/NCT02409680-a525f01e",
        "nct_id": "NCT02409680",
        "kind": "outcome",
        "participants": 11544,
        "risk_difference": {
          "value": -0.007203883308640434,
          "lower": -0.01407070269491475,
          "upper": -0.000373542906154432
        },
        "group_1": "189 of 5,780",
        "group_2": "230 of 5,764",
        "difference": "-0.7 points",
        "interval": "-1.4 to -0.0",
        "trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
      },
      {
        "id": "NCT02409680-db11942d",
        "title": "Intervention Arm vs Placebo Arm: Incidence of Perinatal Mortality",
        "summary": "264 of 5779 against 309 of 5763; risk difference -0.8 points, 95% interval -1.6 to -0.0; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
        "record": "/library/comparisons/NCT02409680-db11942d",
        "nct_id": "NCT02409680",
        "kind": "outcome",
        "participants": 11542,
        "risk_difference": {
          "value": -0.007935263283862057,
          "lower": -0.015893222638065328,
          "upper": -0.000003573639746051044
        },
        "group_1": "264 of 5,779",
        "group_2": "309 of 5,763",
        "difference": "-0.8 points",
        "interval": "-1.6 to -0.0",
        "trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=43",
  "request_id": "DfAHkDbCfNuHBLpH"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?